<span id="midArticle_start"/> May 26 Onxeo SA :
<span id="midArticle_0"/>* Onxeo announces final data from completed phase ii trial of Validive for the prevention of severe oral mucositis in head and neck cancer patients
<span id="midArticle_1"/> <span class="first-article-divide"/> <span class="second-article-divide"/>* These positive results provide basis for a phase 3 trial to further evaluate efficacy of Validive, which Onxeo plans to initiate by end 2015 See also: Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
<span id="midArticle_2"/> <span class="third-article-divide"/>
<span id="midArticle_0"/>* Onxeo announces final data from completed phase ii trial of Validive for the prevention of severe oral mucositis in head and neck cancer patients
<span id="midArticle_1"/> <span class="first-article-divide"/> <span class="second-article-divide"/>* These positive results provide basis for a phase 3 trial to further evaluate efficacy of Validive, which Onxeo plans to initiate by end 2015 See also: Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
<span id="midArticle_2"/> <span class="third-article-divide"/>
via Smart Health Shop Forum http://ift.tt/1cgLcXz
No comments:
Post a Comment